Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Hepatology Reports
Published in: Current Hepatology Reports 3/2019

01-09-2019 | Hepatitis B | Hepatitis B (JK Lim, Section Editor)

Community-Based Strategies to Improve Screening, Diagnosis and Linkage to Care for Patients with Chronic Hepatitis B

Authors: Monica Robotin, Jacob George

Published in: Current Hepatology Reports | Issue 3/2019

Login to get access

Abstract

Purpose of Review

Chronic hepatitis B (CHB) places 3.5% of the world population at risk of dying from liver failure or liver cancer. Effective antiviral therapies can change disease outcomes, provided that CHB screening and linkage to care can be delivered at population level, to reach the vast numbers of undiagnosed people. We therefore reviewed the experience of community-based CHB screening programs reported in the English literature since 2014.

Recent Findings

Twenty papers met eligibility criteria and only one originated from a low-income country. The two randomised studies found that culturally tailored hepatitis education increased hepatitis testing. Successful linkage to care was facilitated by partnerships with community-based organisations and the use of bilingual patient navigators. Point of care testing and chain referral sampling were successfully tested in two programs.

Summary

These studies demonstrated that community-based interventions can screen large numbers of people and could deliver the population-level outcomes required to meet the WHO targets of hepatitis B elimination.
Literature
1.
2.
Gellert L, Jalaludin B, Levy M. Hepatocellular carcinoma in Sydney south west: late symptomatic presentation and poor outcome for most. Intern Med J. 2007;37(8):516–22.CrossRef
3.
Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661–2.CrossRef
4.
5.
Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the global burden of disease study 2013. Lancet. 2016;388(10049):1081–8.
6.
Juon HS, Strong C, Kim F, Park E, Lee S. Lay health worker intervention improved compliance with hepatitis B vaccination in Asian Americans: randomized controlled trial. PLoS One. 2016;11(9):e0162683.CrossRef
7.
Kwong SL, Stewart SL, Aoki CA, Chen MS. Disparities in hepatocellular carcinoma survival among Californians of Asian ancestry, 1988 to 2007. Cancer Epidemiol Biomark Prev. 2010;19(11):2747–57.CrossRef
8.
Trinh-Shevrin C, Pollack HJ, Tsang T, Park J, Ramos MR, Islam N, et al. The Asian American hepatitis B program: building a coalition to address hepatitis B health disparities. Prog Community Health Partnersh. 2011;5(3):261–71.
9.
Supramaniam R, et al. Cancer incidence in New South Wales migrants 1991 to 2001. Sydney: The Cancer Council NSW; 2006.
10.
Altekruse S, McGlynn K, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27(9):1485–91.CrossRef
11.
McDermott S, DesMeules M, Lewis R, Gold J, Payne J, Lafrance B, et al. Cancer incidence among Canadian immigrants, 1980-1998: results from a national cohort study. J Immigr Minor Health. 2011;13(1):15–26.
12.
Haworth EA, Soni Raleigh V, Balarajan R. Cirrhosis and primary liver cancer amongst first generation migrants in England and Wales. Ethn Health. 1999;4(1–2):93–9.CrossRef
13.
Visser O, van Leeuwen FE. Cancer risk in first generation migrants in North-Holland/Flevoland, the Netherlands, 1995-2004. Eur J Cancer. 2007;43(5):901–8.CrossRef
14.
Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52(3):886–93.
15.
Papatheodoridis GV, Manolakopoulos S, Touloumi G, Nikolopoulou G, Raptopoulou-Gigi M, Gogos C, et al. Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort. J Viral Hepat. 2015;22(2):120–7.
16.
Toy M, Veldhuijzen IK, de Man RA, Richardus JH, Schalm SW. Potential impact of long-term nucleoside therapy on the mortality and morbidity of active chronic hepatitis B. Hepatology. 2009;50(3):743–51.CrossRef
17.
Nayagam S, Thursz M, Sicuri E, Conteh L, Wiktor S, Low-Beer D, et al. Requirements for global elimination of hepatitis B: a modelling study. Lancet Infect Dis. 2016;16(12):1399–408.
18.
IOM (Institute of Medicine), Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C., IOM, Editor. 2010, Institute of Medicine: Washington DC.
19.
Cowie, B. and H.Kelly, Outcomes of a complex dynamic mathematical model of hepatitis B virus in Australia. (PP-027), in 20th Conference of the Asian Pacific Association for the Study of the Liver (APASL); . 2010, Hepatology International Beijing, China p. 27.
20.
Hatzakis A, Wait S, Bruix J, Buti M, Carballo M, Cavaleri M, et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J Viral Hepat. 2011;18(Suppl 1):1–16.
21.
Cohen C, Holmberg SD, McMahon BJ, Block JM, Brosgart CL, Gish RG, et al. Is chronic hepatitis B being undertreated in the United States? J Viral Hepat. 2011;18(6):377–83.
22.
Hu KQ, Pan CQ, Goodwin D. Barriers to screening for hepatitis B virus infection in Asian Americans. Dig Dis Sci. 2011;56(11):3163–71.CrossRef
23.
Ma GX, Fang CY, Shive SE, Toubbeh J, Tan Y, Siu P. Risk perceptions and barriers to hepatitis B screening and vaccination among Vietnamese immigrants. J Immigr Minor Health. 2007;9(3):213–20.CrossRef
24.
Nguyen CT, Lin SY. Hepatitis B screening in Asian and Pacific islanders: new guidelines, old barriers. J Immigr Minor Health. 2015;17(5):1585–7.CrossRef
25.
Xu K, Watanabe-Galloway S, Rochling FA, Zhang J, Farazi PA, Peng H, et al. Practice, knowledge, and barriers for screening of hepatocellular carcinoma among high-risk Chinese patients. Annals of Global Health. 2017;83(2):281–92.
26.
Zhou K, Fitzpatrick T, Walsh N, Kim JY, Chou R, Lackey M, et al. Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses. Lancet Infect Dis. 2016;16:1409–22.
27.
Ferrante JM, Winston DG, Chen PH, de la Torre AN. Family physicians' knowledge and screening of chronic hepatitis and liver cancer. Fam Med. 2008;40(5):345–51.PubMed
28.
Lai CJ, Nguyen TT, Hwang J, Stewart SL, Kwan A, McPhee SJ. Provider knowledge and practice regarding hepatitis B screening in Chinese-speaking patients. J Cancer Educ. 2007;22(1):37–41.CrossRef
29.
Robotin M, Patton Y, George J. Getting it right: the impact of a continuing medical education program on hepatitis B knowledge of Australian primary care providers. Int J Gen Med. 2013;6:115–22.CrossRef
30.
Status of Vietnamese Health: Santa Clara County, California, 2011, C.o.S.C.P.H. Department, Editor. 2011, Public Health Department Santa Clara.
31.
Robotin MC, George J. Community-based hepatitis B screening: what works? Hepatol Int. 2014;8(4):478–92.CrossRef
32.
van der Veen YJ, et al. Cultural tailoring to promote hepatitis B screening in Turkish Dutch: a randomized control study. Health Promot Int. 2013;29(4):692–704.CrossRef
33.
Zuure FR, Bouman J, Martens M, Vanhommerig JW, Urbanus AT, Davidovich U, et al. Screening for hepatitis B and C in first-generation Egyptian migrants living in the Netherlands. Liver Int. 2013;33(5):727–38.
34.
Ma GX, Gao W, Tan Y, Chae WG, Rhee J. A community-based participatory approach to a hepatitis B intervention for Korean Americans. Prog Community Health Partnersh. 2012;6(1):7–16.CrossRef
35.
Bailey MB, et al. San Francisco Hep B free: a grassroots community coalition to prevent hepatitis B and liver Cancer. J Community Health. 2010;36(4):538–51.
36.
Hwang JP, Mohseni M, Gor BJ, Wen S, Guerrero H, Vierling JM. Hepatitis B and hepatitis C prevalence and treatment referral among Asian Americans undergoing community-based hepatitis screening. Am J Public Health. 2010;100(Suppl 1):S118–24.CrossRef
37.
Robinson T, Bullen C, Humphries W, Hornell J, Moyes C. The New Zealand hepatitis B screening Programme: screening coverage and prevalence of chronic hepatitis B infection. N Z Med J. 2005;118(1211):U1345.PubMed
38.
Marineau M, Tice AD, Taylor-Garcia D, Akinaka KT, Lusk H, Ona F. Culturally sensitive strategies designed to target the silent epidemic of hepatitis B in a Filipino community. Hawaii Med J. 2007;66(6):154–6.PubMed
39.
Chen CH, Yang PM, Huang GT, Lee HS, Sung JL, Sheu JC. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc. 2007;106(2):148–55.CrossRef
40.
Lee J, Lok AS, Chen J. Hepatitis B prevalence among Asian Americans in Michigan: an assessment to guide future education and intervention strategies. J Community Health. 2010;35(5):534–42.CrossRef
41.
Lin SY, Chang ET, So SK. Why we should routinely screen Asian American adults for hepatitis B: a cross-sectional study of Asians in California. Hepatology. 2007;46(4):1034–40.CrossRef
42.
Buster EH, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology. 2008;135(2):459–67.CrossRef
43.
Mostert MC, Richardus JH, de Man RA. Referral of chronic hepatitis B patients from primary to specialist care: making a simple guideline work. J Hepatol. 2004;41(6):1026–30.CrossRef
44.
Robotin MC, Kansil MQ, Porwal M, Penman AG, George J. Community-based prevention of hepatitis-B-related liver cancer: Australian insights. Bull World Health Organ. 2014;92(5):374–9.CrossRef
45.
46.
Ward JW. Strategies for expanding access to HBV and HCV testing and Care in the United States: the CDC hepatitis testing and linkage to care initiative, 2012-2014. Public Health Rep. 2016;131(Suppl 2):1–4.CrossRef
47.
• Chandrasekar E, et al. A Novel Strategy to Increase Identification of African-Born People With Chronic Hepatitis B Virus Infection in the Chicago Metropolitan Area, 2012–2014. Prev Chronic Dis. 2016;13:E118 Trialled chain referral sampling to encourage testing and engagement in care of uninsured and marginalised African-born people; used patient navigators. CrossRef
48.
Juon HS, Lee S, Strong C, Rimal R, Kirk GD, Bowie J. Effect of a liver cancer education program on hepatitis B screening among Asian Americans in the Baltimore-Washington metropolitan area, 2009-2010. Prev Chronic Dis. 2014;11:130258.CrossRef
49.
• Ma GX, et al. A Community-Based Randomized Trial of Hepatitis B Screening Among High-Risk Vietnamese Americans. Am J Public Health. 2017;107(3):433–40 Cluster RCT of multilevel intervention offering interactive in-language education and patient navigators vs. general information; outcomes: screening rates. Used a participatory approach to enhance intervention effects and enhance its sustainability. CrossRef
50.
Nguyen K, van Nguyen T, Shen D, Xia V, Tran D, Banh K, et al. Prevalence and presentation of hepatitis B and C virus (HBV and HCV) infection in Vietnamese Americans via serial community serologic testing. J Immigr Minor Health. 2015;17(1):13–20.
51.
Strong C, Hur K, Kim F, Pan J, Tran S, Juon HS. Sociodemographic characteristics, knowledge and prevalence of viral hepatitis infection among Vietnamese Americans at community screenings. J Immigr Minor Health. 2015;17(1):298–301.CrossRef
52.
Barragan NC, et al. A case study of a hepatitis B screening and blood pressure assesment program in Los Angeles County, 2012-2013. Prev Chronic Dis. 2015;12:E19.CrossRef
53.
Stornaiuolo G, Cuniato V, Cuomo G, Nocera E, Brancaccio G, de Rosa M, et al. Active recruitment strategy in disadvantaged immigrant populations improves the identification of human immunodeficiency but not of hepatitis B or C virus infections. Dig Liver Dis. 2014;46(1):62–6.
54.
Beckett GA, et al. Early identification and linkage to care of persons with chronic hepatitis B virus infection--three U.S. sites,2012-2014. MMWR Morb Mortal Wkly Rep. 2014;63(18):399–401.PubMedPubMedCentral
55.
Chandrasekar E, Kaur R, Song S, Kim KE. A comparison of effectiveness of hepatitis B screening and linkage to care among foreign-born populations in clinical and nonclinical settings. J Multidiscip Healthc. 2015;8:1–9.CrossRef
56.
Dang JH, Chen MS Jr. Increasing hepatitis B testing and linkage to Care of Foreign-Born Asians, Sacramento, California, 2012-2013. Public Health Rep. 2016;131(Suppl 2):119–24.CrossRef
57.
•• Harris AM, et al. Testing and Linking Foreign-Born People with Chronic Hepatitis B Virus Infection to Care at Nine U.S. Programs, 2012–2014. Public Health Rep. 2016;131(Suppl 2):20–8 Summary results from a prospective cohort drawn from population groups with a HBV prevalence>2%, based on their country of birth. Nine pilot sites conducted targeted screening of 23,144 participants; linkage to primary care providers was achieved in 83% of HBsAg+ve people. Data collected using a common dataset. Authors provide insights into success factors and recommendations for how to increase testing uptake. CrossRef
58.
• Hyun CS, et al. Chronic hepatitis B in Korean Americans: decreased prevalence and poor linkage to care. BMC Infect Dis. 2016;16(1):415 Summarises findings of a large-scale screening and awareness campaign targeting Korean Americans. Through 128 separate community events, tested 7,199 people, with HBV prevalence of 2.4%. Identified role of education and navigation in facilitating linkage to care. CrossRef
59.
Hyun CS, Ventura WR, Kim SS, Yoon S, Lee S. A community- based hepatitis B linkage-to-care program: a case study on Asian Americans chronically infected with hepatitis B virus. Hepatol Med Policy. 2016;1:6.CrossRef
60.
Navarro N, Lim N, Kim J, Joo E, Che K, Runyon BA, et al. Lower than expected hepatitis B virus infection prevalence among first generation Koreans in the U.S.: results of HBV screening in the Southern California Inland Empire. BMC Infect Dis. 2014;14:269.
61.
• Shankar H, et al. A Novel Collaborative Community-Based Hepatitis B Screening and Linkage to Care Program for African Immigrants. Clin Infect Dis. 2016;62(Suppl 4):S289–97 Novel partnership involving a community-based organisation, an academic medical center and community health centers to provide comprehensive screening and linkage to care of underserved / unisured people from African countries. Used culturally targeted patient navigators. CrossRef
62.
Walters J, Sullivan A. Early identification and linkage to Care of Foreign-Born People with chronic hepatitis B virus infection, Multnomah County, Oregon, 2012-2014. Public Health Rep. 2016;131(Suppl 2):105–11.CrossRef
63.
•• Coenen S, et al. Clinical impact of five large-scale screening projects for chronic hepatitis B in Chinese migrants in the Netherlands. Liver Int. 2016;36(10):1425–32 First large-scale community based screening and treatment intervention in high risk Chinese residents in a European country. Combination of outreach with direct clinic referal ensured high referral and treatment rates. CrossRef
64.
Richter C, et al. Screening for chronic hepatitis B and C in migrants from Afghanistan, Iran, Iraq, the former soviet republics, and Vietnam in the Arnhem region. Netherlands Epidemiol Infect. 2014;142(10):2140–6.CrossRef
65.
•• Lemoine M, et al. Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study. Lancet Glob Health. 2016;4(8):e559–67 First large-scale screen-and-treat program in the general population in a low-resource country in Africa. Used point-of-care testing and trained fieldworkers and achieved high screening coverage and linkage to care.
66.
•• Robotin MC, et al. Using a chronic hepatitis B Registry to support population-level liver cancer prevention in Sydney, Australia. Clin Epidemiol. 2018;10:41–9 Established a disease Registry enrolling patients with CHB diagnosed in primary care. Specialist referral based upon risks stratification by primary care providers, which reduced unnecessary specialist referrals. Validated assumptions of the economic level, including antiviral treatment in 18% of those enrolled.
67.
Juon HS, Strong C, Oh TH, Castillo T, Tsai G, Oh LDH. Public health model for prevention of liver cancer among Asian Americans. J Community Health. 2008;33(4):199–205.CrossRef
68.
Richter C, et al. Hepatitis B prevalence in the Turkish population of Arnhem: implications for national screening policy? Epidemiol Infect. 2012;140(4):724–30.CrossRef
69.
Perumalswami PV, Factor SH, Kapelusznik L, Friedman SL, Pan CQ, Chang C, et al. Hepatitis outreach network: a practical strategy for hepatitis screening with linkage to care in foreign-born communities. J Hepatol. 2013;58(5):890–7.
70.
Veldhuijzen IK, Wolter R, Rijckborst V, Mostert M, Voeten HA, Cheung Y, et al. Identification and treatment of chronic hepatitis B in Chinese migrants: results of a project offering on-site testing in Rotterdam The Netherlands. J Hepatol. 2012;57(6):1171–6.
71.
Robotin M, et al. Characteristics of chronic hepatitis B infection in SW Sydney: clinical correlates and policy implications. In: in 9th Australasian Viral Hepatitis Conference. Australia: Alice Springs; 2014.
72.
World Health Organization, Guidelines on hepatitis B and C testing. 2017, World Health Organization Geneva.
73.
Hutton DW, Tan D, So SK, Brandeau ML. Cost-effectiveness of screening and vaccinating Asian and Pacific islander adults for hepatitis B. Ann Intern Med. 2007;147(7):460–9.CrossRef
74.
Veldhuijzen IK, Toy M, Hahné SJM, de Wit GA, Schalm SW, de Man RA, et al. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective. Gastroenterology. 2010;138(2):522–30.
75.
Robotin MC, Kansil M, Howard K, George J, Tipper S, Dore GJ, et al. Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening. J Hepatol. 2009;50(5):990–8.
76.
Lemoine M, Nayagam S, Thursz M. Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges. Futur Virol. 2013;8(4):371–80.CrossRef
77.
Zhou K, Fitzpatrick T, Walsh N, Kim JY, Chou R, Lackey M, et al. Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses. Lancet Infect Dis. 2016;16(12):1409–22.
78.
Shapiro AE, et al. Completion of the tuberculosis care cascade in a community-based HIV linkage-to-care study in South Africa and Uganda. J Int AIDS Soc. 2018;21(1):e25065.CrossRef
79.
Hermann K, van Damme W, Pariyo GW, Schouten E, Assefa Y, Cirera A, et al. Community health workers for ART in sub-Saharan Africa: learning from experience--capitalizing on new opportunities. Hum Resour Health. 2009;7:31.
80.
Dunbar EL, Wroe EB, Nhlema B, Kachimanga C, Gupta R, Taylor C, et al. Evaluating the impact of a community health worker programme on non-communicable disease, malnutrition, tuberculosis, family planning and antenatal care in Neno, Malawi: protocol for a stepped-wedge, cluster randomised controlled trial. BMJ Open. 2018;8(7):e019473.
81.
Busza J, Dauya E, Bandason T, Simms V, Chikwari CD, Makamba M, et al. The role of community health workers in improving HIV treatment outcomes in children: lessons learned from the ZENITH trial in Zimbabwe. Health Policy Plan. 2018;33(3):328–34.
82.
Nayagam S, Conteh L, Sicuri E, Shimakawa Y, Suso P, Tamba S, et al. Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in the Gambia: an economic modelling analysis. Lancet Glob Health. 2016;4(8):e568–78.
83.
Allain JP. Screen-and-treat for chronic hepatitis B: an overdue issue for sub-Saharan Africa. Lancet Glob Health. 2016;4(8):e507–8.CrossRef
84.
Glasgow RE, Askew S, Purcell P, Levine E, Warner ET, Stange KC, et al. Use of RE-AIM to address health inequities: application in a low-income community health center based weight loss and hypertension self-management program. Transl Behav Med. 2013;3(2):200–10.
85.
Glasgow RE, Estabrooks PE. Pragmatic applications of RE-AIM for health care initiatives in community and clinical settings. Prev Chronic Dis. 2018;15:E02.CrossRef
86.
Glasgow RE, Klesges LM, Dzewaltowski DA, Estabrooks PA, Vogt TM. Evaluating the impact of health promotion programs: using the RE-AIM framework to form summary measures for decision making involving complex issues. Health Educ Res. 2006;21(5):688–94.CrossRef
87.
Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health. 1999;89(9):1322–7.CrossRef
88.
Forman J, Heisler M, Damschroder LJ, Kaselitz E, Kerr EA. Development and application of the RE-AIM QuEST mixed methods framework for program evaluation. Prev Med Rep. 2017;6:322–8.CrossRef
Metadata
Title
Community-Based Strategies to Improve Screening, Diagnosis and Linkage to Care for Patients with Chronic Hepatitis B
Authors
Monica Robotin
Jacob George
Publication date
01-09-2019
Publisher
Springer US
Published in
Current Hepatology Reports / Issue 3/2019
Electronic ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-019-00485-x

Other articles of this Issue 3/2019

Current Hepatology Reports 3/2019 Go to the issue

Hepatitis B (JK Lim, Section Editor)

Economic Analyses to Inform and Support Health Policy for Chronic Hepatitis B Treatment

Drug-Induced Liver Injury (P Hayashi, Section Editor)

Bile Duct Injury Due to Drug-Induced Liver Injury

Drug-Induced Liver Injury (P Hayashi, Section Editor)

The Role of Liver Biopsy in Drug-Induced Liver Injury

Hepatitis B (JK Lim, Section Editor)

The Role of Traditional Chinese Medicines (TCM) and Other Complementary and Alternative Medicines (CAM) in the Management of Chronic Hepatitis B

Hepatitis B (JK Lim, Section Editor)

Role of HBsAg Testing in the Management of Patients with Chronic HBV

Drug-Induced Liver Injury (P Hayashi, Section Editor)

Drug-Induced Liver Injury Due to Nonsteroidal Anti-inflammatory Drugs
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits